Targeting hyperactive mitochondria in activated HSCs and inhibition of liver fibrogenesis in mice using sorafenib complex micelles
Authors:
- 8 December 2024
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 669, 125058
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81371675)
- Natural Science Foundation of Hunan Province (2024JJ5342)
This publication has 59 references indexed in Scilit:
- Selective inhibition of glycolysis in hepatic stellate cells and suppression of liver fibrogenesis with vitamin A-derivative decorated camptothecin micellesActa Biomaterialia, 2023
- CREKA-modified liposomes target activated hepatic stellate cells to alleviate liver fibrosis by inhibiting collagen synthesis and angiogenesisActa Biomaterialia, 2023
- Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapyActa Biomaterialia, 2022
- High throughput interrogation of human liver stellate cells reveals microenvironmental regulation of phenotypeActa Biomaterialia, 2021
- Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosisBiochemical and Biophysical Research Communications, 2021
- Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approvalAdvanced Drug Delivery Reviews, 2020
- Naringenin loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in hepatic fibrosisBiomedical Microdevices, 2020
- JNK activation and translocation to mitochondria mediates mitochondrial dysfunction and cell death induced by VDAC opening and sorafenib in hepatocarcinoma cellsBiochemical Pharmacology, 2019
- Hepatic stellate cells as key target in liver fibrosisAdvanced Drug Delivery Reviews, 2017
- Structure and function of hepatic stellate cellsMedical Molecular Morphology, 2004